Contineum Therapeutics, INC Schedule 13G passive stakes

Balyasny Asset Management L.P. and affiliated entities have reported an increase in their beneficial ownership of Contineum Therapeutics, Inc. Class A Common Stock to 7.14%.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 931,709 shares, representing 2.8% of Contineum Therapeutics, Inc.'s Class A Common Stock.

RA Capital Management and its affiliates report a 4% beneficial ownership stake in Contineum Therapeutics, Inc. as of March 31, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 2,417,723 shares, representing 7.4% of Contineum Therapeutics, Inc.'s Class A Common Stock.

Millennium Management LLC and Israel A. Englander have reported a 5.1% beneficial ownership stake in Contineum Therapeutics, Inc. via a Schedule 13G filing.

Janus Henderson Group plc has reported a 7.9% beneficial ownership stake in Contineum Therapeutics, Inc.'s Class A Common Stock.

Balyasny Asset Management and its affiliates have reported a 7.6% beneficial ownership stake in Contineum Therapeutics, Inc.'s Class A Common Stock.

Franklin Advisers, Inc., a subsidiary of Franklin Resources, Inc., has reported a 6.2% beneficial ownership stake in Contineum Therapeutics, Inc. Class A Common Stock.

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. reported beneficial ownership of 7.7% of Contineum Therapeutics, Inc.'s Class A Common Stock.

Perceptive Advisors and affiliates report a reduced beneficial ownership of 3.2% in Contineum Therapeutics, Inc. Class A Common Stock.

Franklin Advisers, Inc., a subsidiary of Franklin Resources, Inc., has disclosed an 8.9% beneficial ownership stake in Contineum Therapeutics, Inc.'s Class A Common Stock.

RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Contineum Therapeutics, Inc. following an at-the-market offering.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have filed an amended Schedule 13G, confirming their beneficial ownership of 7.5% of Contineum Therapeutics, Inc.'s Class A Common Stock.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a passive beneficial ownership of 5.6% in Contineum Therapeutics, Inc.'s Class A Common Stock.

Sectoral Asset Management Inc. and Jerome G. Pfund have filed an amended Schedule 13G, disclosing their beneficial ownership of Class A Common Stock in Contineum Therapeutics, Inc., with Pfund holding 4.99% and Sectoral holding 4.2% as of December 31, 2024.